SAN

77.96

+0.13%↑

UCB

251.5

+1%↑

SHL.DE

36.94

+0.74%↑

ARGX

588.4

0%↓

VIE

31.68

+0.86%↑

SAN

77.96

+0.13%↑

UCB

251.5

+1%↑

SHL.DE

36.94

+0.74%↑

ARGX

588.4

0%↓

VIE

31.68

+0.86%↑

SAN

77.96

+0.13%↑

UCB

251.5

+1%↑

SHL.DE

36.94

+0.74%↑

ARGX

588.4

0%↓

VIE

31.68

+0.86%↑

SAN

77.96

+0.13%↑

UCB

251.5

+1%↑

SHL.DE

36.94

+0.74%↑

ARGX

588.4

0%↓

VIE

31.68

+0.86%↑

SAN

77.96

+0.13%↑

UCB

251.5

+1%↑

SHL.DE

36.94

+0.74%↑

ARGX

588.4

0%↓

VIE

31.68

+0.86%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

26 1.36

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.3

Max

26.45

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	-10.85% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	1. apr 2026

Turustatistika
By TradingEconomics
Turukapital	1.4B
Eelmine avamishind	24.64
Eelmine sulgemishind	26

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. märts 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23. märts 2026, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23. märts 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23. märts 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23. märts 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23. märts 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23. märts 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23. märts 2026, 22:42 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

23. märts 2026, 22:42 UTC

Market Talk

Uudisväärsed sündmused

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23. märts 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23. märts 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23. märts 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23. märts 2026, 22:18 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23. märts 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23. märts 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23. märts 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. märts 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23. märts 2026, 21:10 UTC

Uudisväärsed sündmused

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23. märts 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk

Tulu

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

-10.85% langus

12 kuu keskmine prognoos

Keskmine 23 EUR -10.85%

Kõrge 23 EUR

Madal 23 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.